DDInter1936 DDInter1628
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Vinblastine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Vinblastine {u} (Compound) upregulates {v} (Gene) DAPK3
DAPK3 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Vinblastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Vinblastine {u} (Compound) upregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Vinblastine {u} (Compound) downregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Vinblastine {u} (Compound) downregulates {v} (Gene) KIAA0907
KIAA0907 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Vinblastine {u} (Compound) upregulates {v} (Gene) STK25
STK25 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Vinblastine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Vinblastine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Vinblastine {u} (Compound) upregulates {v} (Gene) DAPK3
DAPK3 {u} (Gene) regulates {v} (Gene) AKAP8L
AKAP8L {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Vinblastine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Vinblastine (Compound) upregulates DAPK3 (Gene) and DAPK3 (Gene) is bound by Ruxolitinib (Compound)
Vinblastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Vinblastine (Compound) upregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Vinblastine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ruxolitinib (Compound)
Vinblastine (Compound) downregulates KIAA0907 (Gene) and KIAA0907 (Gene) is downregulated by Ruxolitinib (Compound)
Vinblastine (Compound) upregulates STK25 (Gene) and STK25 (Gene) is downregulated by Ruxolitinib (Compound)
Vinblastine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Vinblastine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Vinblastine (Compound) upregulates DAPK3 (Gene) and DAPK3 (Gene) regulates AKAP8L (Gene) and AKAP8L (Gene) is upregulated by Ruxolitinib (Compound)